9 studies were found.

1.		No longer recruiting	Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma Conditions: stage III melanoma; Stage IV Melanoma; Recurrent Melanoma
2.		No longer recruiting	Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
3.		No longer recruiting	Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer Conditions: recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
4.		No longer recruiting	Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Conditions: refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
5.		Recruiting	Genasense™ (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects with Chronic Lymphocytic Leukemia Condition: Chronic Lymphocytic Leukemia
6.		No longer recruiting	Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia Condition: recurrent adult acute myeloid leukemia
7.		No longer recruiting	Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Conditions: stage II chronic lymphocytic leukemia; stage IV chronic lymphocytic leukemia; refractory chronic lymphocytic leukemia; ...
8.		Recruiting	Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia Conditions: Chronic Lymphocytic Leukemia; CLL
9.		No longer recruiting	Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma Conditions: Non-Hodgkin's Lymphoma; Relapsed Lymphoma; Refractory Lymphoma; Low-Grade Lymphoma; Intermediate-Grade Lymphoma